Connect Biopharma Holdings Limited — Form 6-K Summary
Business Context and Reporting Period
Foreign private issuer reporting financial results on September 13, 2022, for the six months ended June 30, 2022. Connect Biopharma is a clinical-stage biotechnology company developing immune modulators for autoimmune and inflammatory diseases, including CBP-201 for atopic dermatitis and asthma and CBP-307 for ulcerative colitis. The interim financial statements are unaudited, prepared under IAS 34, and presented primarily in RMB.
Key Financial Metrics
| Metric | Six months ended June 30, 2022 | Comparable 2021 period |
|---|---|---|
| Revenue | None; no approved products | None |
| Research and development expense | RMB 340.8 million | RMB 217.8 million |
| Administrative expense | RMB 71.8 million | RMB 48.0 million |
| Operating loss | RMB 401.8 million | RMB 268.4 million |
| Net loss | RMB 401.3 million, or USD 59.8 million | RMB 942.5 million |
| Basic and diluted loss per share | RMB 7.3 loss per share | RMB 20.1 loss per share |
| Net cash used in operating activities | RMB 342.5 million, or USD 51.0 million | RMB 252.8 million |
| Net cash used in investing activities | RMB 491.3 million, or USD 73.2 million | RMB 32.6 million |
| Cash and cash equivalents at June 30 | RMB 948.8 million, or USD 141.4 million | RMB 2,025.0 million at June 30, 2021 |
| Cash, cash equivalents and investments at June 30, 2022 | RMB 1.429 billion, or approximately USD 212.9 million | Not stated on a comparable basis |
Gross and operating margins are not meaningful because the Company has generated no revenue. Accumulated losses were approximately RMB 2.8 billion, or USD 414.0 million, at June 30, 2022. Total liabilities were RMB 145.7 million, consisting primarily of trade payables, accruals and lease liabilities; the filing does not report significant interest-bearing debt.
Material Changes Versus the Prior Comparable Period
- R&D expense increased RMB 123.0 million, or approximately 56%, driven mainly by expanded clinical-trial, drug-manufacturing and personnel costs.
- Clinical-trial and drug-manufacturing expenses increased to approximately RMB 287.9 million from RMB 189.1 million, reflecting continued development of CBP-201 and CBP-307.
- Administrative expense increased RMB 23.9 million, primarily from higher personnel costs, stock-based compensation, professional fees, insurance and recruiting expenses.
- Net loss declined by RMB 541.2 million because the 2021 period included a RMB 674.3 million fair-value loss on preferred-rights instruments that were converted into ordinary shares upon the IPO. The 2022 period had no comparable charge.
- Other gains of RMB 9.2 million replaced other losses of RMB 7.6 million, primarily due to foreign-exchange gains and a RMB 1.0 million insurance recovery related to a 2021 phishing scam.
- Operating cash outflow increased to RMB 342.5 million from RMB 252.8 million, while investing cash outflow increased substantially because the Company purchased approximately RMB 521.2 million of financial assets and RMB 11.3 million of property, plant and equipment.
- Cash and cash equivalents declined by approximately RMB 758.1 million from December 31, 2021, partly because cash was transferred into debt investments classified as financial assets at fair value through other comprehensive income.
Guidance, Outlook, Risks and Unusual Items
- Management expects continued significant operating losses and negative operating cash flow while advancing clinical programs, manufacturing candidates, expanding facilities and personnel, seeking regulatory approvals and protecting intellectual property.
- Management believes existing cash, cash equivalents and short-term investments are sufficient to meet operating and capital requirements for at least the next 12 months and supports preparation of the financial statements on a going-concern basis.
- Key development updates included positive top-line results for the CBP-201 global Phase 2b atopic dermatitis trial, completion of enrollment in a China pivotal CBP-201 study, completion of an FDA end-of-Phase 2 meeting, and completion of the induction phase of the global Phase 2 CBP-307 ulcerative colitis trial.
- The Company completed enrollment in a Phase 1 trial for CBP-174 and appointed Dr. Chin Lee as Chief Medical Officer.
- COVID-19-related healthcare disruption may delay or affect clinical trials for CBP-201 and CBP-307. Clinical timelines and costs remain uncertain and may be affected by enrollment, regulatory requirements, safety monitoring, manufacturing and trial-design changes.
- The Company has no current product revenue and may need additional capital in the future, particularly for commercialization if regulatory approval is obtained.
- Approximately RMB 480.4 million of debt investments were held at fair value through other comprehensive income at June 30, 2022; the filing reported a RMB 1.3 million unrealized loss in OCI and no impairment.
- After the reporting period, the Company granted 22,000 stock options on July 26, 2022 and 12,000 options on August 26, 2022.
Important Facts for Investors to Verify
- Confirm the pace of cash utilization and the duration of the stated liquidity runway, including the distinction between cash, short-term investments and long-term investments.
- Review clinical efficacy, safety, enrollment and regulatory milestones for CBP-201, CBP-307 and CBP-174, and assess the potential effect of trial delays or additional regulatory requirements.
- Assess the sustainability of sharply higher R&D spending and the likelihood of additional equity or other financing before commercialization.
- Review the composition, maturity, currency exposure and liquidity of the RMB 480.4 million FVOCI debt-investment portfolio.
- Consider dilution from the 5.7 million outstanding stock options, additional plan reserves and future equity financing.
- Review foreign-exchange controls affecting RMB cash and the Company’s ability to transfer funds from the PRC to other jurisdictions.